JP2022531177A - 神経変性障害を治療するための方法 - Google Patents

神経変性障害を治療するための方法 Download PDF

Info

Publication number
JP2022531177A
JP2022531177A JP2021564246A JP2021564246A JP2022531177A JP 2022531177 A JP2022531177 A JP 2022531177A JP 2021564246 A JP2021564246 A JP 2021564246A JP 2021564246 A JP2021564246 A JP 2021564246A JP 2022531177 A JP2022531177 A JP 2022531177A
Authority
JP
Japan
Prior art keywords
subject
synuclein
administered
disease
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531177A5 (https=
Inventor
ジェイ エス． シュナイダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of JP2022531177A publication Critical patent/JP2022531177A/ja
Publication of JP2022531177A5 publication Critical patent/JP2022531177A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01062—Ganglioside galactosyltransferase (2.4.1.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021564246A 2019-04-29 2020-04-29 神経変性障害を治療するための方法 Pending JP2022531177A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840235P 2019-04-29 2019-04-29
US62/840,235 2019-04-29
PCT/US2020/030409 WO2020223310A2 (en) 2019-04-29 2020-04-29 Methods for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2022531177A true JP2022531177A (ja) 2022-07-06
JP2022531177A5 JP2022531177A5 (https=) 2023-05-10

Family

ID=73029186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564246A Pending JP2022531177A (ja) 2019-04-29 2020-04-29 神経変性障害を治療するための方法

Country Status (5)

Country Link
US (1) US20220226357A1 (https=)
EP (1) EP3962492A4 (https=)
JP (1) JP2022531177A (https=)
CN (1) CN114761021A (https=)
WO (1) WO2020223310A2 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018275A1 (ja) * 2005-08-11 2007-02-15 National Institute Of Advanced Industrial Science And Technology ローリングモデルに基づく、送達媒体の設計
WO2009104649A1 (ja) * 2008-02-22 2009-08-27 片山化学工業株式会社 合成糖脂質含有リポソーム
JP2013508366A (ja) * 2009-10-19 2013-03-07 アミカス セラピューティックス インコーポレイテッド 中枢神経系の変性障害を予防および／または治療するための新規の組成物
JP2014523881A (ja) * 2011-06-22 2014-09-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
WO2017009312A1 (en) * 2015-07-13 2017-01-19 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
JP2017514515A (ja) * 2014-04-08 2017-06-08 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473174A4 (en) * 2009-09-01 2014-02-26 Lz Therapeutics Inc TRANSMUCOSAL GANGLIOSIDE FORMULATIONS
US20140187507A1 (en) * 2012-12-14 2014-07-03 Rutgers, The State University Of New Jersey Treatment of parkinsons disease with glycolipids
WO2017015491A1 (en) * 2015-07-21 2017-01-26 Thomas Jefferson University Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018275A1 (ja) * 2005-08-11 2007-02-15 National Institute Of Advanced Industrial Science And Technology ローリングモデルに基づく、送達媒体の設計
WO2009104649A1 (ja) * 2008-02-22 2009-08-27 片山化学工業株式会社 合成糖脂質含有リポソーム
JP2013508366A (ja) * 2009-10-19 2013-03-07 アミカス セラピューティックス インコーポレイテッド 中枢神経系の変性障害を予防および／または治療するための新規の組成物
JP2014523881A (ja) * 2011-06-22 2014-09-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
JP2017514515A (ja) * 2014-04-08 2017-06-08 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
WO2017009312A1 (en) * 2015-07-13 2017-01-19 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GUSHENG WU ET AL.: "Deficiency of Ganglioside GM1 Correlates With Parkinson’s Disease in Mice and Humans", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 90, JPN6024015348, 2012, pages 1997 - 2008, ISSN: 0005473055 *
JAY S. SCHNEIDER ET AL.: "GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of", SCIENTIFIC REPORTS, vol. 9, JPN7024001614, 2019, pages 1 - 12, ISSN: 0005309628 *
JIANSHE WE ET AL.: "Gangliosides protection against lysosomal pathology of synucleinopathies", AUTOPHAGY, vol. 5, JPN7024001613, 2009, pages 860 - 861, ISSN: 0005309629 *
JIANSHE WEI ET AL.: "Protective Role of Endogenous Gangliosides for Lysosomal Pathology in a Cellular Model of Synucleino", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 174, JPN7024001612, 2009, pages 1891 - 1909, ISSN: 0005309630 *
ZAK MARTINEZ ET AL.: "GM1 Specifically Interacts with R-Synuclein and Inhibits Fibrillation", BIOCHEMISTRY, vol. 46, JPN6024015347, 2007, pages 1868 - 1877, ISSN: 0005473056 *
ZAK MARTINEZ ET AL.: "GM1 Specifically Interacts with α-Synuclein and Inhibits Fibrillation", BIOCHEMISTRY, vol. 46, JPN6024048566, 2007, pages 1868 - 1877, ISSN: 0005473057 *
高田 昌彦: "アルファシヌクレイン発現によるパーキンソン病サルモデルの開発", 日本生物学的精神医学会誌, vol. 24, JPN6024048567, 2013, pages 57 - 61, ISSN: 0005473058 *

Also Published As

Publication number Publication date
WO2020223310A3 (en) 2020-12-10
EP3962492A4 (en) 2023-05-31
WO2020223310A2 (en) 2020-11-05
EP3962492A2 (en) 2022-03-09
US20220226357A1 (en) 2022-07-21
CN114761021A (zh) 2022-07-15

Similar Documents

Publication Publication Date Title
US20240226203A9 (en) Compositions and methods of treating huntington's disease
US20230295663A1 (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
US12116589B2 (en) Treatment of amyotrophic lateral sclerosis (ALS)
JP7190352B2 (ja) 認知保護を提供しつつ疾患の発症及び進行を遅らせるための遺伝子治療を用いた神経変性疾患の治療方法
US20220333131A1 (en) Modulatory polynucleotides
US11903985B2 (en) Gene therapies for lysosomal disorders
JP2020079234A (ja) 筋萎縮性側索硬化症および他の脊髄障害のための遺伝子治療
JP2020050660A (ja) 脊髄疾患の遺伝子療法
US11999974B2 (en) Gene therapies for lysosomal disorders
US20230227802A1 (en) Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
JP2016503405A (ja) タンパク質症を処置するための組成物および方法
KR20220107243A (ko) Apoe 유전자 요법
KR102618947B1 (ko) 뇌 질환을 치료하기 위한 방법 및 조성물
EP3481433B1 (en) Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
US20230310654A1 (en) Gene therapies for lysosomal disorders
KR20220164708A (ko) AAV 유전자 요법을 위한 무-CpG ITR
US20230285596A1 (en) Compositions and methods for the treatment of niemann-pick type c1 disease
JP2022531177A (ja) 神経変性障害を治療するための方法
KR20250156211A (ko) 글루코실세라미다제 베타 1 결핍증과 관련된 신경 장애의 치료를 위한 조성물 및 방법
CN119326898A (zh) 靶向星形胶质细胞修复脑内磷稳态的基因疗法
WO2025016362A1 (zh) 基于脑内磷稳态促进剂的疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230427

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241202